November 24, 2021
Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference
November 19, 2021
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
November 11, 2021
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
Alkermes worked with The Harris Poll to conduct a survey exploring drinking patterns during the COVID-19 pandemic and people’s motivations to seek help.
Learn more about our ongoing clinical research program for nemvaleukin alfa, our lead immuno-oncology candidate. The investigational IL-2 variant immunotherapy is currently being studied across clinical trials evaluating intravenous and subcutaneous dosing.
In a recent interview with Informa Connect's Xconomy, our Chief Operating Officer, Blair Jackson, discusses our ambitions and our evolving strategy in neuroscience and oncology.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.